Patient characteristics
. | cGVHD, n = 17 . | Controls, n = 23 . |
|---|---|---|
| Age, y | 43 (range, 29-55) | 41 (range, 18-54) |
| Sex (M/F) | 10/7 | 14/9 |
| Diagnosis | ||
| Acute leukemia | 6 | 9 |
| Chronic myelogenous leukemia | 5 | 8 |
| Myeloma | 2 | 0 |
| Lymphoma | 1 | 5 |
| Myelodysplastic syndrome | 3 | 1 |
| Donor* | ||
| HLA-identical related donor | 14 | 20 |
| HLA-matched VUD | 3 | 3 |
| Preparative regimen†‡ | ||
| Standard | 16 | 18 |
| Reduced-intensity | 1 | 5 |
| Source of HSC | ||
| BM | 6 | 12 |
| PBSC | 11 | 11 |
| In vivo T-cell depletion§ | 4 | 8 |
| Acute GVHD grade II–IV∥ | 8 | 1 |
| Immunosuppression at time of analysis∥ | 14 | 8 |
| Time after HSCT for analysis, mo | 17 (range, 4-71) | 11 (range, 4-110) |
. | cGVHD, n = 17 . | Controls, n = 23 . |
|---|---|---|
| Age, y | 43 (range, 29-55) | 41 (range, 18-54) |
| Sex (M/F) | 10/7 | 14/9 |
| Diagnosis | ||
| Acute leukemia | 6 | 9 |
| Chronic myelogenous leukemia | 5 | 8 |
| Myeloma | 2 | 0 |
| Lymphoma | 1 | 5 |
| Myelodysplastic syndrome | 3 | 1 |
| Donor* | ||
| HLA-identical related donor | 14 | 20 |
| HLA-matched VUD | 3 | 3 |
| Preparative regimen†‡ | ||
| Standard | 16 | 18 |
| Reduced-intensity | 1 | 5 |
| Source of HSC | ||
| BM | 6 | 12 |
| PBSC | 11 | 11 |
| In vivo T-cell depletion§ | 4 | 8 |
| Acute GVHD grade II–IV∥ | 8 | 1 |
| Immunosuppression at time of analysis∥ | 14 | 8 |
| Time after HSCT for analysis, mo | 17 (range, 4-71) | 11 (range, 4-110) |
VUD indicates volunteer unrelated donor; HSC, hematopoietic stem cells; BM, bone marrow.
HLA typing was performed by molecular techniques for HLA class I A, B, and C and for class II HLA DRB1 and DQB1, in all donors and recipients
Standard conditioning was performed using total body irradiation (TBI) and cyclophosphamide, TBI and melphalan, or busulfan and cyclophosphamide. Reduced intensity conditioning was performed using fludarabine and melphalan or BCNU, cytarabine arabinoside, etoposide, and melphalan
GVHD prophylaxis was with cyclosporine/methotrexate in the majority of patients (n = 36), with the exception of 4 patients who received cyclosporine alone
In vivo T-cell depletion with alemtuzumab was administered before transplantation to a subset of patients who were recipients of volunteer unrelated HSCs or underwent reduced ntensity conditioning
P < .01, cGVHD versus controls